الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 106 |  |  |
| | | from | 106 | | |
Abstract
The aim of the present work is to study the expression of SOX2 in urinary bladder carcinoma, and to investigate the relationship between its expression and clinicopathological data of the patients. Additionally, the change in the expression pattern of SOX2 in the primary tumour and the corresponding lymph node metastases was evaluated.
The present study included 60 in UBC cases randomly selected from the archive of histopathological laboratories of Minia University Hospital, Minia Oncology Center and Kasr-ELAini Hospital.
SOX2 expression scoring ranges between –ve/low and high. Thirty four cases (56.7%) showed –ve/low expression while 26 cases (43.3%) showed high expression. Significant association was found between SOX2 expression and tumour type, tumour grade, stage, state of muscle invasion and presence of lymph node metastases (p.= 0.012, 0.005, 0.045, 0.014 and <0.001 respectively). SOX2 expression was investigated in those cases with lymph node positive metastasis and concordance rate of 66.6% was found between the expression in primary tumour and lymph node metastasis. Interestingly, 29.17% of those cases exhibited change in SOX2 expression pattern to higher expression in their lymph node metastases compared to the primary tumour tissue.
Our results strongly suggest that UBC patients whose tumor exhibit high SOX2 immunoexpression, have increased risk of cancer progression and poor prognostic feature, in comparison to patients whose tumors express –ve/low expression scores.
6.2. Conclusion
The present study highlighted the important role of SOX2 in urinary bladder tumourogenesis, progression and development of LN metastases. Among the clinicopathological parameters investigated, we found a positive significant association with higher tumour grades, advanced stage and LN metastases, specifically. Collectively, our results suggest that SOX2 expression may help to detect UBC patient group with poor prognostic features. Correspondingly, as this study stated, SOX2 seems to have a chief role in development of LN metastases.
A concordance rate of 66.6% was detected between primary tumour and their LN metastases regarding SOX2 expression. However, higher scores were seen in 7 cases suggesting the role of SOX2 in acquiring the metastatic ability in tumour cells.